Bruker Corporation (BRKR)
割高ファンダメンタル
33
株価
$64.75
時価総額
$9.87B
パート1 · 企業の価値
概要
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Named by Bruker in its own 10-K, Thermo Fisher sells mass spectrometers, molecular spectroscopy and electron microscopy systems to the same pharmaceutical, academic and industrial laboratories Bruker serves worldwide.
Agilent competes head-on in mass spectrometry, chromatography coupling and molecular spectroscopy for life-science and applied-chemistry labs, the core of Bruker's CALID business.
Waters sells LC-MS platforms to the same pharmaceutical QC, proteomics and food-safety customers that buy Bruker's timsTOF and triple-quadrupole instruments.
Through SCIEX and Leica Microsystems, Danaher bids against Bruker for the same mass-spectrometry and high-end microscopy budgets in research and clinical laboratories.
Shimadzu offers a full analytical-instrument catalogue — mass spectrometry, spectrophotometry, surface analysis — and is Bruker's main Japanese rival in Asian academic and industrial accounts.
JEOL is the main alternative supplier of NMR and electron-microscopy systems, the market where Bruker's BioSpin division holds its strongest position.
貸借対照表と流動性
売上高
$3.50B
直近12か月（2026/6/30まで）
純利益
$-71M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$43M
自己資本合計
$2.46B
負債合計
$3.73B
流動比率
1.85
利払い倍率
0.50
負債/EBITDA
6.33
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$46.11
現在株価
$64.75
安全マージン
-40.4%
適正価値レンジ
$29.97 - $62.25
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-0.4%
P/B レシオ
4.11
P/FCF
105.06
粗利益率
46.4%
ROIC
-0.5%
収益性レーダー
価値創造（経済的モート）
ROIC
-0.5%
WACC
10.0%
ROIC − WACC
-10.5 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（10）
- Price CAGR 10.91%
- Gross Margin 46.4%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 11.6%
- Analyst Consensus 62% Buy
- Earnings Surprise avg 19.0%
- Share Dilution -61.5%
- Piotroski F-Score 5/9
不合格（13）
- EPS shows upward trend
- ROIC -0.5%
- P/FCF 105.06
- P/B Ratio 4.11
- Operating Margin -0.9%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -2.9%
- Net Margin Trend -2.0% vs 2.3%
データなし（4）
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
低品質：会計処理を調査してください
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & President | 65 |
| Mr. Gerald N. Herman CPA | Executive VP & CFO | 67 |
| Dr. Mark R. Munch Ph.D. | Corporate Executive VP and President of Bruker Nano Group & Corporate | 63 |
| Mr. Juergen W. Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | 70 |
| Mr. Thomas M. Bures | Chief Accounting Officer | 50 |
| Mr. J. Brent Alldredge J.D. | Senior VP, General Counsel, Secretary & Global Head of Compliance | 50 |
| Dr. Wolfgang Pusch Ph.D. | President of Bruker Microbiology & Infection Diagnostics Group | - |
| Dr. Burkhard Prause Ph.D. | President and CEO of Bruker Energy & Supercon Technologies, Inc. | 58 |
監査リスク
7
取締役会リスク
6
報酬リスク
6
株主権利リスク
5
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for BRKR, sourced from Markets Gazette.